Fresh analysis reveals that patients who discontinue popular GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise programs.
Published data in a prominent medical journal demonstrates that while obese individuals frequently drop about a fifth of their body weight while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.
"Individuals using these treatments need to be cognizant of the danger of rapid weight regain when the therapy ends," stated researcher Dr. Susan Jebb.
That rate of regain implies a reversion to starting mass within about 18 months.
Analyzing Therapies
The analysis, which examined dozens of studies involving thousands of patients, contrasted the results of GLP-1 agonists with other pills.
Scientists emphasize that individuals who shed pounds through lifestyle changes alone typically have a more gradual weight regain—approximately 0.1 kg a month—after stopping.
Understanding the Fast Rebound
Experts believe the way of the injections is key to understanding the heightened regain.
These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing the hormone concentrations several times higher than normal might result in the system to generate a reduced amount of its own natural hormone, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement means appetite is uncontrolled, making excessive eating much more probable."
A Chronic Condition?
Health authorities recommend the injections for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Many experts contend that, considering the significant potential of relapse, the treatment should be considered ongoing.
This view is reinforced by pharmaceutical companies, who note that the results "underscore the chronic nature of obesity," comparing it to managing conditions like hypertension.
Patient Testimonies
Users who have come off the jabs report a sudden return of hunger.
"I experienced something flipping and you become extremely hungry," said an individual.
This challenge is exacerbated if patients have not developed lasting dietary or behavioural modifications during therapy.
Widespread Interest
Survey data suggest that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is more common among females than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
In conclusion, researchers caution that while these medications are potent agents for shedding pounds, they are not a magic fix and lasting health benefits hinges on combined behavioural changes.
